Clinical trial NCT04542590: Natural History of Patients With PH3 and a History of Stone Events
Official title: A Natural History Study of Patients With Genetically Confirmed Primary Hyperoxaluria Type 3 and, as Applicable Per Age, a History of Stone Events
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Primary Hyperoxaluria Type 3
Keywords: primary hyperoxaluria
PH3
observational
kidney stones
nephrocalcinosis
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2020-09-09
Enrollment: 7
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is a natural history study in adults, adolescents, and children (starting from birth) with genetically confirmed PH3 who have a history of stone events during the last 3 years and/or the presence of preexisting stones detected by renal ultrasounds at Screening, and an eGFR \> 30 mL/min/1.73 m2 or serum creatinine below the 97th percentile for patients younger than 12 months old.

Brief summary: This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.

Detailed description: The relationship between the level of Uox and the incidence of kidney stones and/or nephrocalcinosis in patients with PH3 has not been established. The goal of this study is to record 24-hour Uox levels and the incidence of new stone formation and/or the degree of nephrocalcinosis in patients with PH3 over time.

Potential participants are screened over an up-to-7 week period according to the eligibility criteria and will then be followed every 6 months over an up-to-2-year period to determine the annualized new stone formation rate (number of new stones being formed per year) and the change in the degree of nephrocalcinosis (if applicable).

New stone formation is defined as occurrence of any of the following:

* Spontaneous stone passage in the absence of pre-existing stones
* Stone passage occurring without change in the number of pre-existing stones detected by renal ultrasound
* Appearance of new stones on renal ultrasound or 100% or more growth of a pre-existing stone (estimated area)
* Surgical removal of newly formed stones Note: Spontaneous passage or surgical removal of pre-existing stones does not meet the criteria for new stone formation.

This is a non-interventional study that will last up to 2 years.

Eligibility criteria: Key inclusion criteria

* Genetically confirmed PH3
* For participants at least 2 years of age, history of stone events (defined as presence of calcifications in the urinary tract and/or kidney, their relative location, and the number and size of stones) during the last 3 years and/or presence of pre-existing stones detected by renal ultrasound at Screening
* Uox ≥ 0.7 mmol/24 hours (adjusted per 1.73 m2 BSA in participants \< 18 years of age) OR if not able to collect 24-hour urine, average spot Uox to creatinine ratio at Screening above the 95th percentile for age:

  * \> 220 mmol/mol in participants \< 6 months
  * \> 170 mmol/mol in participants from 6 months to \< 12 months
  * \> 130 mmol/mol in participants 12 months to \< 2 years
  * \> 100 mmol/mol in participants from 2 to \< 3 years and
  * \> 80 mmol/mol in participants from 3 to 5 years
* eGFR at Screening ≥ 30 mL/min or for infants aged less than 12 months, serum creatinine below the 97th percentile of a healthy population

Key Exclusion Criteria:

* Prior or planned liver transplant within study period
* Currently receiving dialysis or anticipating dialysis during study period
* Unwillingness to comply with study procedures

Primary outcomes:
measure: Collect stone formation data in PH3 patients
timeFrame: Assess participants' stone formation rates over the course of 2 years
measure: Assess relationship between urine oxalate (Uox) levels and stone formations in PH3 patients
timeFrame: Measure participants' Uox levels over the course of 2 years
measure: Collect data on the degree of nephrocalcinosis in PH3 patients
timeFrame: Assess the change in nephrocalcinosis grade over the course of 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Clinical Trial Site
state: Massachusetts
city: New York
country: United States
facility: Clinical Trial Site
state: New York
city: Toronto
country: Canada
facility: Clinical Trial Site
state: Ontario
city: Heidelberg
country: Germany
facility: Clinical Trial Site
city: Warsaw
country: Poland
facility: Clinical Trial Site
city: London
country: United Kingdom
facility: Clinical Trial Site
Study officials:
affiliation: Dicerna, A Novo Nordisk Company
name: Verity Rawson
role: STUDY_DIRECTOR
References: